Reports prognostic markers related to immune suppression and treatment sensitivity in luminal breast cancer, suggesting targets for precision therapy.
LCN2, RRAS2, LRG1, and LTF can be used as prognostic markers for Luminal breast cancer, related to immune suppression and tumor progression, and the high-risk group is more sensitive to PI3K inhibitors and chemotherapy drugs, providing potential targets for precision treatment.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: